Matthew Miles to Bronchodilator Agents
This is a "connection" page, showing publications Matthew Miles has written about Bronchodilator Agents.
Connection Strength
0.941
-
Miles MC, Donohue JF, Ohar JA. Nebulized arformoterol: what is its place in the management of COPD? Ther Adv Respir Dis. 2013 Apr; 7(2):81-6.
Score: 0.411
-
Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs. 2012 Feb 12; 72(3):301-8.
Score: 0.390
-
Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
Score: 0.118
-
Yan H, Deshpande DA, Misior AM, Miles MC, Saxena H, Riemer EC, Pascual RM, Panettieri RA, Penn RB. Anti-mitogenic effects of ß-agonists and PGE2 on airway smooth muscle are PKA dependent. FASEB J. 2011 Jan; 25(1):389-97.
Score: 0.022